reference library

/reference library
reference library2018-06-08T14:23:35-07:00

This website features a collection of links to outside resources, many of which were cited in The Captured Economy, for readers interested in learning more about regressive regulation.

To filter the reference library by topic, please use the links on a topic page or open this page on a full-size screen and use the provided menu.

(When) Does Patent Protection Spur Cumulative Research Within Firms?

Ashish Arora, Sharon Belenzon, Matt Marx, and Dror Shvadron

NBER

June 2021

We estimate the effect of patent protection on follow-on investments in corporate scientific research. We exploit a new method for identifying an exogenous reduction in the protection a granted patent…
Read more

Bankrupt Innovative Firms

Song Ma, Joy Tianjiao Tong, and Wei Wang

NBER

May 2021

This paper studies how innovative firms manage their innovation portfolios after filing for Chapter 11 reorganization using three decades of data. We find that they sell off core (i.e., technologically…
Read more

Optimal Patent Policy for Pharmaceutical Industry

Tanja Saxell, Tuomas Takalo, and Olena Izhak

VATT Institute for Economic Research

July 2020

We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about generic producers’ responses to changes in the effective duration and scope of new drug patents….
Read more

Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic

Frank Tietze, Pratheeba Vimalnath, Leonidas Aristodemou, and Jenny Molloy

IEEE Transactions on Engineering Management

June 18, 2020

A pandemic calls for large-scale action across national and international innovation systems in order to mobilize resources for developing and manufacturing crisis-critical products efficiently and in the huge quantities needed….
Read more

Technological Improvement Rate Estimates for All Technologies: Use of Patent Data and an Extended Domain Description

Anuraag Singh, Giorgio Triulzi, and Christopher L. Magee

SSRN

Apr 30, 2020

In this work, we attempt to provide a comprehensive granular account of the pace of technological change. More specifically, we survey estimated yearly performance improvement rates for nearly all definable…
Read more

The Patents-Based Pharmaceutical Development Process: Rationale, Problems, and Potential Reforms

John H Barton and Ezekiel J Emanuel

Journal of the American Medical Association

Oct 26, 2005

The pharmaceutical industry is facing substantial criticism from many directions, including financial barriers to access to drugs in both developed and developing countries, high profits, spending on advertising and marketing,…
Read more

Estimating The Cost Of Delayed Generic Drug Entry To Medicaid

Chintan V. Dave, Michael S. Sinha, Reed F. Beall, and Aaron S. Kesselheim

Health Affairs

June 2020

Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid…
Read more

Estimating The Cost Of Delayed Generic Drug Entry To Medicaid

Chintan V. Dave, Michael S. Sinha, Reed F. Beall, and Aaron S. Kesselheim

Health Affairs

June 2020

Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid…
Read more

Innovation in the U.S. Government

Joshua R. Bruce and John M. de Figueiredo

NBER

May 2020

This paper examines the U.S. government’s intramural research and development efforts over a 40-year period, drawing together multiple human capital, government spending, and patent datasets. The U.S. Federal Government innovates…
Read more

Patents, Innovation, and Development

Bronwyn H. Hall

NBER

May 2020

I survey some recent research on the role of patents in encouraging innovation and growth in developing economies, beginning with a brief history of international patent systems and facts about…
Read more

Financing Vaccines for Global Health Security

Jonathan T. Vu, Benjamin K. Kaplan, Shomesh Chaudhuri, Monique K. Mansoura, and Andrew W. Lo

NBER

May 2020

Recent outbreaks of infectious pathogens such as Zika, Ebola, and COVID-19 have underscored the need for the dependable availability of vaccines against emerging infectious diseases (EIDs). The cost and risk…
Read more

The Anticompetitive Effects of Common Ownership: The Case of Paragraph IV Generic Entry

Jin Xie and Joseph Gerakos

PAEA Papers and Proceedings

May 2020

Brand-name pharmaceutical companies often file lawsuits against generic drug manufacturers that challenge the monopoly status of patent-protected drugs. Institutional horizontal shareholdings, measured by the generic shareholders’ ownership in the brand-name…
Read more

Innovation α: What Do IP-Intensive Stock Price Indexes Tell Us about Innovation?

Carol Corrado, David Martin and Qianfan Wu

AEA Papers and Proceedings

May 2020

Patents and other intellectual property (IP) have grown in relative importance in investments and market capitalizations of public firms (e.g., Corrado and Hulten 2010). This paper illustrates the construction of…
Read more

Expected Profits and The Scientific Novelty of Innovation

David Dranove, Craig Garthwaite, and Manuel I. Hermosilla

NBER

May 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for firms to develop new products in the future. While existing research demonstrates…
Read more

Truly Standard-Essential Patents? A Semantics-Based Analysis

Lorenz Brachtendorf, Fabian Gaessler, and Dietmar Harhoff

Centre for Economic Policy Research

May 2020

Standard-essential patents (SEPs) have become a key element of technical coordination in standard-setting organizations. Yet, in many cases, it remains unclear whether a declared SEP is truly standard-essential. To date,…
Read more

Scientific Grant Funding

Pierre Azoulay and Danielle Li

NBER

March 2020

This chapter provides an overview of grant funding as an innovation policy tool aimed at both practitioners and science policy scholars. We first discuss how grants relate to other contractual…
Read more

How Much Can Pharma Lose?

Sean Dickson and Jeromie Ballreich

Westhealth Policy Center

December 2019

Whenever policymakers consider approaches to reduce drug spending, the pharmaceutical industry sings a familiar refrain— any reduction in drug manufacturer revenues will cause investment to wither, depriving manufacturers of the…
Read more

Blind Spot: How the COVID-19 Outbreak Shows the Limits of Pharma’s Monopoly Model

Zain Rizvi

Public Citizen

February 19, 2020

As yet another coronavirus spreads around the globe, scientists are once again trying to develop new treatments and vaccines. Much remains unknown about this family of viruses. But we know…
Read more

Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies

Fred D. Ledley, Sarah Shonka McCoy, and Gregory Vaughan

JAMA

March 3, 2020

Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry’s ability to innovate and provide essential medicines. This cross-sectional study…
Read more

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

Olivier J. Wouters, PhD1; Martin McKee, MD, DSc2; Jeroen Luyten, PhD

JAMA

March 3, 2020

The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. Data were analyzed on new therapeutic…
Read more

Approaching intellectual property scholarship differently: A qualitative research review and agenda

Shobita Parthasarathy

Science and Public Policy

February 27, 2020

Social and policy interest in intellectual property, and patents, in particular, is growing. This is reflected in the rise of scholarly inquiry on the topic beyond the legal community, including…
Read more

Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents

Jeffrey Clemens, Parker Rogers

NBER

January 2020

We analyze wartime prosthetic device patents to investigate how procurement policy affects the cost, quality, and quantity of medical innovation. Analyzing whether inventions emphasize cost and/or quality requires generating new…
Read more

Medicines and Intellectual Property: 10 Years of the WHO Global Strategy

Germán Velásquez

South Centre

December 2019

The negotiations of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) (2006-2008), undertaken by the Member States of the World Health Organization (WHO), were the result…
Read more

Economic Perspectives on FRAND

Roya Ghafele

2019

The economic valuation of intellectual property is an area with which IP professionals still need to fully come to grips with. In the context of Standard Essential Patents (SEPs), the…
Read more

Is the Supreme Court’s Patentable Subject Matter Test Overly Ambiguous? An Empirical Test

Jason Reinecke

SSRN

July 2, 2019

In four cases handed down between 2010 and 2014, the Supreme Court articulated a new two-step patent eligibility test that drastically reduced the scope of patent protection for software inventions….
Read more

Prophetic Patents

Janet Freilich

SSRN

June 25, 2018

In most contexts, making up data is forbidden – considered fraudulent, even immoral. Not so in patents. Patents often contain experimental data, and it is perfectly acceptable for these experiments…
Read more

The Paradoxes of Patenting: Invention and Its Diffusion in 18th- and 19th-Century Britain, France, and North America

Christine MacLeod

Technology and Culture

October 1991

This article deals with a period of transition for most patent systems in Europe and North America, from instruments of royal prerogative power to specialized and statute-based weapons of capitalist…
Read more

Appropriating the Returns from Industrial Research and Development

Richard C. Levin, Alvin K. Klevorick, Richard R. Nelson, Sidney G. Winter

Brookings Papers on Economic Activity

1987

This paper describes the results of an inquiry into appropriability conditions in more than one hundred manufacturing industries. We discuss how this information has been and might be used to…
Read more

Trends in Prices of Popular Brand-Name Prescription Drugs in the United States

Nathan E. Wineinger, Yunyue Zhang, and Eric J. Topol

JAMA Network

May 31, 2019

High and continually increasing pharmaceutical drug spending is a major health and health policy concern in the United States.This economic evaluation of drug prices focuses on 49 top-selling brand-name medications…
Read more

Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests

Secretary’s Advisory Committee on Genetics, Health, and Society

Department of Health and Human Services

April 2010

In keeping with our mandate to provide advice on the broad range of policy issues raised by the development and use of genetic technologies as well as our charge to…
Read more

The Uneasy Case for Software Copyrights Revisited

Pamela Samuelson

The George Washington Law Review

September 2011

Forty years ago, Justice Stephen Breyer expressed serious doubts about the economic soundness of extending copyright protection to computer programs in his seminal article, The Uneasy Case for Copyright. A…
Read more

Intellectual Property Law and the Right to Repair

Leah Chan Grinvald and Ofer Tur-Sinai

Fordham Law Review

May 2019

In recent years, there has been a growing push towards state legislation that would provide consumers with a “right to repair” their products. Currently 18 states have pending legislation that…
Read more

Intellectual Property in the New Technological Age: 2017 – Chapters 1 and 2

Peter S. Menell, Mark A. Lemley, Robert P. Merges

UC Berkley Law School

2017

“The 2017 Edition reflects the following principal developments: Trade Secrets: Congress passed the Defend Trade Secrets Act of 2016, one of the most momentous changes in the history of trade…
Read more

The Patent Troll: Benign Middleman or Stick-Up Artist?

David S. Abrams, Ufuk Akcigit, Gokhan Oz, and Jeremy G. Pearce

NBER

March 2019

How do non-practicing entities (“Patent Trolls”) impact innovation and technological progress? Although this question has important implications for industrial policy, little direct evidence about it exists. This paper provides new…
Read more

Two Errors in the Ninth Circuit’s Qualcomm Opinion

Thomas F. Cotter

Two Errors in the Ninth Circuit’s Qualcomm Opinion

September 10 2020

On August 11, 2020, the Ninth Circuit handed down its opinion in Federal Trade Commission v. Qualcomm Inc., reversing the district court’s judgment in favor of the FTC. This essay…
Read more

The ESG-Innovation Disconnect: Evidence from Green Patenting

Lauren Cohen, Umit G. Gurun, and Quoc H. Nguyen

NBER

October 2020

No firm or sector of the global economy is untouched by innovation. In equilibrium, innovators will flock to (and innovation will occur where) the returns to innovative capital are the…
Read more

The Access to Knowledge Mobilization and the New Politics of Intellectual Property

Amy Kapczynski

Yale Law Journal

2008

Intellectual Property law was once an arcane subject. Today it is at the center of some of the most highly charged political contests of our time. In recent years, college…
Read more

From Revolving Doors to Regulatory Capture? Evidence from Patent Examiners

Haris Tabakovic and Thomas G. Wollmann

NBER

May 2018

Many regulatory agency employees are hired by the firms they regulate, creating a “revolving door” between government and the private sector. We study these transitions using detailed data from the…
Read more

Disclosure and Subsequent Innovation: Evidence from the Patent Depository Library Program

Jeffrey L. Furman, Markus Nagler, and Martin Watzinger

NBER

May 2018

How important is information disclosure through patents for subsequent innovation? Although disclosure is regarded as essential to the functioning of the patent system, legal scholars have expressed considerable skepticism about…
Read more

Does Winning a Patent Race Lead to More Follow-On Innovation?

Neil Thompson and Jeffrey M. Kuhn

Journal of Legal Analysis

June 30, 2020

Competition between firms to invent and patent an idea, or “patent racing,” has been much discussed in theory, but seldom analyzed empirically. This article introduces an empirical way to identify…
Read more

Eighteen Years After Doha: An Analysis of the Use of Public Health TRIPS Flexibilities in Africa

Yousuf A. Vawda and Bonginkosi Shozi

The South Centre

February 2020

As we observe the 18th anniversary of the Doha Declaration on the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights) and Public Health, it is appropriate to take…
Read more

Academics’ Motives, Opportunity Costs and Commercial Activities Across Fields

Wesley M. Cohen, Henry Sauermann, and Paula Stephan

June 2018

Scholarly work seeking to understand academics’ commercial activities often draws on abstract notions of the institution of science and of the representative scientist. Few scholars have examined whether and how…
Read more

An Assessment of the Impact of the America Invents Act and the Patent Trial and Appeal Board on the US Economy

The Perryman Group

The Perryman Group

June 2020

In a recent study, The Perryman Group (TPG), a world-renowned group of economists widely used and respected by industry and government, measured the effect of the AIA and PTAB on…
Read more

The Impact of Information Technology on the Diffusion of New Pharmaceuticals

Kenneth J. Arrow, L. Kamran Bilir, and Alan Sorensen

American Economic Journal: Applied Economics

July 2020

Do information differences across US physicians contribute to treatment disparities? This paper uses a unique new dataset to evaluate how changes in physician access to a decision-relevant drug database affect…
Read more

How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013

Frank R. Lichtenberg

NBER

January 2019

“We analyze the role that the launch of new drugs has played in reducing the number of years of life lost (YLL) before 3 different ages (85, 70, and 55)…
Read more

Copying in Patent Law

Christopher Anthony Cotropia and Mark A. Lemley

North Carolina Law Review

June 2009

Patent law is virtually alone in intellectual property (IP) in punishing independent development. To infringe a copyright or trade secret, defendants must copy the protected IP from the plaintiff, directly…
Read more

Crafting Intellectual Property Rights: Implications for Patent Assertion Entities, Litigation, and Innovation

Josh Feng and Xavier Jaravel

American Economic Journal

September 13, 2016

We show that examiner-driven variation in patent rights leads to quantitatively large impacts on several patent outcomes, including patent value, citations, and litigation. Notably, Patent Assertion Entities (PAEs) overwhelmingly purchase…
Read more

Overpatented, Overpriced

i-Mak

February 2019

This report analyzes the twelve best selling drugs in the United States and reveals that drugmakers file hundreds of patent applications – the vast majority of which are granted –…
Read more

From Incentive to Commodity to Asset: How International Law is Reconceptualizing Intellectual Property

Rochelle Cooper Dreyfuss and Susy Frankel

Michigan Journal of International Law

October 2014

Domestic patent, copyright and trademark regimes are traditionally justified on an incentive rationale. While international intellectual property agreements are nominally aimed at harnessing global markets to expand incentives, this article…
Read more

Innovative startup firms and the patent system

Bronwyn Hall

VoxEU

July 19, 2018

Patent protection is assumed to benefit entrepreneurs seeking investment, because patents signal quality and are an asset that can be resold if a startup fails. This column argues that the…
Read more

Who Profits from Patents? Rent-Sharing at Innovative Firms

Patrick Kline, Neviana Petkova, Heidi Williams, and Owen Zidar

NBER

November 2018

This paper analyzes how patent-induced shocks to labor productivity propagate into worker compensation using a new linkage of US patent applications to US business and worker tax records. We infer…
Read more

Annual Intellectual Property Report to Congress

United States Intellectual Property Enforcement Coordinator

Office of the President of the United States

February 2019

The United States government is taking a targeted, practical, and comprehensive approach toward addressing intellectual property policy and strategy. The goal is to ensure a level playing field for American…
Read more

Is Intellectual Property the Root of All Evil? Patents, Copyrights, and Inequality

Dean Baker

Center for Economic and Policy Research

October 2018

This paper raises three issues on the relationship between intellectual property and inequality. The first is a simple logical point. Patents, copyrights, and other forms of intellectual property are public…
Read more

Patent Trolls and Startup Employment

Ian Appel, Joan Farre-Mensa, and Elena Simintzi

SSRN

October 17, 2018

We analyze how frivolous patent-infringement claims made by non-practicing entities (NPEs, or “patent trolls”) affect startups’ ability to grow and create jobs, innovate, and raise capital. Our identification strategy exploits…
Read more

Patent Trolls and the Market for Acquisitions

Arash Dayani

SSRN

November 15, 2019

Frivolous patent-infringement claims increase the cost of innovation for small businesses and force them to exit via premature and discounted acquisitions. This study investigates the effect of abusive patent-infringement claims…
Read more

Explaining Criminal Sanctions in Intellectual Property Law

Irina D. Manta

Journal of Law & Innovation

October 29, 2019

This symposium piece first seeks to unpack the relationship between intellectual property infringement and property offenses, and then to understand how the connection between the two has informed when the…
Read more

Beyond Patents

Jeffrey Funk

Issues in Science and Technology

Summer 2018

I argue that the growing dominance of patent analysis not only fails to provide valuable and reliable insight into innovation processes, but is a smoke screen that prevents social scientists…
Read more

Intellectual property rights affect the pattern of trade

Jenny Lin and William Lincoln

VoxEU

July 6, 2018

Disagreements over intellectual property rights policies have been a major roadblock in recent trade agreement talks, and the issue has also been a pillar of critiques of globalisation. This column…
Read more

Knowledge Spillovers and Corporate Investment in Scientific Research

Ashish Arora, Sharon Belenzon, and Lia Sheer

American Economic Review

March 2021

Using data on 800,000 corporate publications and patent citations to these publications between 1980 and 2015, we study how corporate investment in research is linked to its use in the…
Read more

eBay, the Right to Exclude, and the Two Classes of Patent Owners

Paul R. Michel and John T. Battaglia

Patently-O Patent Law Journal

2020

The entire point of a healthy patent system is on spurring invention and investment, by rewarding inventor and investor alike, big or small, with exclusive rights of limited duration, for…
Read more

Opening up Military Innovation: Causal Effects of ‘Bottom-Up’ Reforms to U.S. Defense Research

Sabrina T. Howell, Jason Rathje, John Van Reenen, and Jun Wong

NBER

April 2021

When investing in research and development (R&D), institutions must decide whether to take a top-down approach — soliciting a particular technology — or a bottom-up approach in which innovators suggest…
Read more

The Role of Antitrust in Preventing Patent Holdup

Carl Shapiro and Mark A. Lemley

SSRN

August 4 2020

Patent holdup has proven one of the most controversial topics in innovation policy, in part because companies with a vested interest in denying its existence have spent tens of millions…
Read more

Drug Pricing Investigation (Celgene and Bristol Myers Squibb—Revlimid)

House Committee on Oversight and Reform Staff

September 2020

This staff report describes the actions of Celgene Corporation and Bristol Myers Squibb Company in repeatedly raising the price of Revlimid, a critical drug to treat multiple myeloma and other…
Read more

Owning Knowledge: A Unified Theory of Patent Eligibility

Talha Syed

SSRN

September 23 2020

Patent law’s doctrine of ineligible subject matter is widely agreed to be in a bad state of repair. Even those welcoming the Supreme Court’s return to express subject-matter bars have…
Read more

Big Pharma’s Big Lie: The Truth About Innovation & Drug Prices

Patients For Affordable Drugs

3 February 2021

Big Pharma’s innovation argument just does not stand up to scrutiny. We can’t allow drug corporations to continue to hide behind their threat that if we do anything to curb…
Read more

The U.S. District Court for the Northern District of Illinois Dismisses Antitrust Case Challenging Patent Thicket (Humira)

Michael A. Carrier

e-Competitions

August 20, 2020

Whether behavior relating to a patent thicket presents an antitrust issue is a nuanced question. But a recent ruling involving the biologic Humira shows how not to decide these issues….
Read more

Issuing and Tailoring Patent Injunctions – A Cross-Jurisdictional Comparison and Synthesis

Jorge L. Contreras and Martin Husovec

SSRN

27 March 2021

This chapter is from the edited volume “Injunctions in Patent Law: A Trans-Atlantic Dialogue on Flexibility and Tailoring” (Jorge Contreras & Martin Husovec, eds., Cambridge Univ. Press, forthcoming). It offers…
Read more

Research and Development in the Pharmaceutical Industry

David Austin and Tamara Hayford

Congressional Budget Office

April 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs…
Read more

The effect of patent expiration on sales of branded competitor drugs in a therapeutic class

Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and Stuart Schweitzer

Journal of Generic Medicines

11 July 2019

Patent expiration is a consequential event for not only the drug undergoing patent expiration, but also the therapeutic class in which the drug is contained. Market dynamics change significantly for…
Read more

First-mover Advantage and the Private Value of Public Science

Ashish Arora, Sharon Belenzon & Bernardo Dionisie

NBER

March 2021

Technical progress increasingly relies on the use of scientific knowledge. But if much of this knowledge is in the public domain, can it be a source of private value? We…
Read more

Science as a Public Good: Public Use and Funding of Science

Yian Yin, Yuxiao Dong, Kuansan Wang, Dashun Wang, and Benjamin Jones

NBER

April 2021

Knowledge of how science is consumed in public domains is essential for a deeper understanding of the role of science in human society. While science is heavily supported by public…
Read more

Linguistic Metrics for Patent Disclosure: Evidence from University Versus Corporate Patents

Nancy Kong, Uwe Dulleck, Adam B. Jaffe, Shupeng Sun, and Sowmya Vajjala

Linguistic Metrics for Patent Disclosure: Evidence from University Versus Corporate Patents

September 2020

This paper proposes a novel approach to measure disclosure in patent applications using algorithms from computational linguistics. Borrowing methods from the literature on second language acquisition, we analyze core linguistic…
Read more

Patent Quality: Towards a Systematic Framework for Analysis and Measurement

Kyle W. Higham, Gaétan de Rassenfosse, Adam B. Jaffe

NBER

September 2020

The ‘quality’ of novel technological innovations is extremely variable, and the ability to measure innovation quality is essential to sensible, evidence-based policy. Patents, an often vital precursor to a commercialised…
Read more

Guide for the Granting of Compulsory Licenses and Government Use of Pharmaceutical Patents

Carlos M. Correa

South Centre

April 2020

Like other rights, patent rights are not absolute. There are situations in which their exercise can be limited to protect public interests. Such situations may arise, for instance, when access…
Read more

Biosimilar Competition: Early Learning

Richard G. Frank, Mahnum Shahzad, William B. Feldman, and Aaron S. Kesselheim

NBER

March 2021

Biologics accounted for roughly $145 billion in spending in 2018 (IQVIA, 2019). They are also the fastest growing segment of the pharmaceutical industry. The Biological Price Competition and Innovation Act…
Read more

Covid-19 Pandemic’s Impact on the U.S. Patent System Through November 2020

Nicholas Shine

Patently-O Patent Law Journal

2021

“This essay examines patent abandonment rates and application rates to determine if they can shed light on how the Covid-19 pandemic affected innovation. While the results show temporary perturbations, the…
Read more

Patents, Property, and Prospectivity

Jonathan Masur and Adam Mortara

Patents, Property, and Prospectivity

April 2019

When judges change the legal rules governing patents, those changes are always retroactive. That is, they apply equally to patents that have already been granted and patents that do not…
Read more

Practical Implications of ‘Vaccine Nationalism’: A Short-Sighted and Risky Approach in Response to COVID-19

Muhammad Zaheer Abbas

The South Centre

November 2020

To end the COVID-19 pandemic and ensure a return of normalcy, an effective and safe vaccine is the best hope. The vaccine nationalism approach, adopted by some countries to gain…
Read more

The functions of patents in our societies: innovation, markets, and new firms

Alfonso Gambardella

Centre for Economic Policy Research

April 2021

This article provides a review of the role and functions of patents in society using data and evidence from the economic and management literature. While patents provide private protection to…
Read more

Nonobviousness: Before and After

Dmitry Karshtedt

Iowa Law Review

6 April 2021

The requirement of nonobviousness, codified in 35 U.S.C. § 103, has been called “the ultimate condition of patentability” because of its crucial function of keeping technically trivial inventions out of…
Read more

The Importance of an Effective and Reliable Patent System to Investment in Critical Technologies

Mark F. Schultz

The Importance of an Effective and Reliable Patent System to Investment in Critical Technologies

July 2020

As the U.S. patent system has weakened, venture capital investment shifted away from patentintensive industries. We supplemented our exhaustive review of 14 years of data tracking VC investment by talking…
Read more

Preparing for a Pandemic: Accelerating Vaccine Availability

Amrita Ahuja, Susan Athey, Arthur Baker, Eric Budish, Juan Camilo Castillo, Rachel Glennerster, Scott Duke Kominers, Michael Kremer, Jean Nahrae Lee, Canice Prendergast, Christopher M. Snyder, Alex Tabarrok, Brandon Joel Tan, and Witold Więcek

NBER

February 2021

Vaccinating the world’s population quickly in a pandemic has enormous health and economic benefits. We analyze the problem faced by governments in determining the scale and structure of procurement for…
Read more

What Drives Innovation? Lessons from COVID-19 R&D

Ruchir Agarwal and Patrick Gaule

IZA Institute of Labor Economics

January 2021

To examine the drivers of innovation, this paper studies the global R&D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R&D activity—measured by…
Read more

How Patent Damages Skew Licensing Markets

Erik Hovenkamp and Jonathan Masur

Coase-Sandor Institute for Law and Economics

2016

If a litigated patent has previously been licensed to a third party, the courts generally adopt the terms of the prior agreement as the best measure of damages. However, while…
Read more

Patenting Inventions or Inventing Patents? Strategic Use of Continuations at the USPTO

Cesare Righi and Timothy Simcoe

Patenting Inventions or Inventing Patents? Strategic Use of Continuations at the USPTO

August 2020

Continuations allow inventors to claim technology developed after the original filing date of their patent, leading to concerns about inadvertent infringement and hold-up. We use the link between patents and…
Read more

Idea Diffusion and Property Rights

Boyan Jovanovic and Zhu Wang

NBER

October 2020

We study the innovation and diffusion of technology at the industry level. We derive the full dynamic paths of an industry’s evolution, from birth to its maturity, and we characterize…
Read more

Innovation and Human Capital Policy

John Van Reenen

NBER

April 2021

If innovation is to be subsidized, a natural place to start is to increase the quantity and quality of human capital. Innovation, after all, begins with people. Simply stimulating the…
Read more

What Happened to U.S. Business Dynamism?

Ufuk Akcigit and Sina T. Ates

NBER

April 2019

In the past several decades, the U.S. economy has witnessed a number of striking trends that indicate a rising market concentration and a slowdown in business dynamism. In this paper,…
Read more

Generic Drug Entry Priot to Patent Expiration

FTC

July 2002

“This study examines whether the conduct that the FTC challenged represented isolated instances or is more typical, and whether the 180-day exclusivity and the 30- month stay provisions of the…
Read more

Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets

Rena M. Conti and Ernst R. Berndte

NBER

August 2019

We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA’s National Sales Perspective™ 2004Q4 – 2016Q3 data. We define a unique product market (“molform”), consisting of the…
Read more

The ‘Article of Manufacture’ in 1887

Sarah Burstein

Berkley Tech Law Journal

October 2016

One of the most important questions in contemporary design patent law is how to interpret the phrase “article of manufacture” in 35 U.S.C. § 289. While there has been much…
Read more

Contribution of NIH funding to new drug approvals 2010–2016

Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee, and Fred D. Ledley

PNAS

February 2018

This work examines the contribution of NIH funding to published research associated with 210 new molecular entities (NMEs) approved by the Food and Drug Administration from 2010–2016. We identified >2…
Read more

Irrational Ignorance at the Patent Office

Michael D. Frakes and Melissa F. Wasserman

Vanderbilt Law Review

November 13, 2018

There is widespread belief that the Patent Office issues too many bad patents that impose significant harms on society. At first glance, the solution to the patent quality crisis seems…
Read more

Standing on the Shoulders of Science

Monika Schnitzer and Martin Watzinger

CEPR

May 2019

The goal of science is to advance knowledge, yet little is known about its value for marketplace inventions. While important breakthrough technologies could not have been developed without scientific background,…
Read more

Patent Examiner Specialization

Cesare Righi and Timothy Simcoe/p>

NBER

October 2017

We study the matching of patent applications to examiners at the U.S. Patent and Trademark Office. Using test statistics originally developed to identify industry agglomeration, we find strong evidence that…
Read more

Procrastination in the Workplace: Evidence from the U.S. Patent Office

Michael D. Frakes and Melissa F. Wasserman

NBER

January 2017

Despite much theoretical attention to the concept of procrastination and much exploration of this phenomenon in laboratory settings, there remain few empirical investigations into the practice of procrastination in real…
Read more

Decreasing the Patent Office’s Incentives to Grant Invalid Patents

Michael D. Frakes and Melissa F. Wasserman

The Hamilton Project

December 13, 2017

There is general agreement that the U.S. Patent and Trademark Office is issuing too many invalid patents that are unnecessarily reducing consumer welfare, stunting productive research, and discouraging innovation. In…
Read more

Is the Time Allocated to Review Patent Applications Inducing Examiners to Grant Invalid Patents?: Evidence from Micro-level Application Data

Michael D. Frakes and Melissa F. Wasserman

NBER

December 2014

We explore how examiner behavior is altered by the time allocated for reviewing patent applications. Insufficient examination time may hamper examiner search and rejection efforts, leaving examiners more inclined to…
Read more

Does the U.S. Patent and Trademark Office Grant Too Many Bad Patents?: Evidence From a Quasiexperiement

Michael D. Frakes and Melissa F. Wasserman

Notre Dame Law Review

2015

Many believe the root cause of the patent system’s dysfunction is that the U.S. Patent and Trademark Office (PTO or Agency) is issuing too many invalid patents that unnecessarily drain…
Read more

The Paper Trail of Knowledge Spillovers: Evidence from Patent Interferences

Ina Ganguli, Jeffrey Lin, and Nicholas Reynolds

Federal Reserve Bank of Philidelphia

January 2019

We show evidence of localized knowledge spillovers using a new database of U.S. patent interferences terminated between 1998 and 2014. Interferences resulted when two or more independent parties submitted identical…
Read more